FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ARMISTICE CAPITAL, LLC
2. Issuer Name and Ticker or Trading Symbol

ACHIEVE LIFE SCIENCES, INC. [ ACHV ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

510 MADISON AVENUE, 7TH FLOOR, 
3. Date of Earliest Transaction (MM/DD/YYYY)

6/11/2019
(Street)

NEW YORK, NY 10022
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/11/2019     S    29724   D $4.39   1066202   D   (1)  
Common Stock   6/11/2019     S    0   D $0   1066202   I   See Footnote   (1)
Common Stock   6/11/2019     S    21118   D $4.29   1045084   D   (1)  
Common Stock   6/11/2019     S    0   D $0   1045084   I   See Footnote   (1)
Common Stock   6/11/2019     S    31897   D $3.30   1013187   D   (1)  
Common Stock   6/11/2019     S    0   D $0   1013187   I   See Footnote   (1)
Common Stock   6/11/2019     P    12813   A $3.80   (2) 1026000   D   (1)  
Common Stock   6/11/2019     P    0   A $0   1026000   I   See Footnote   (1)
Common Stock   6/11/2019     S    10000   D $3.64   1016000   D   (1)  
Common Stock   6/11/2019     S    0   D $0   1016000   I   See Footnote   (1)
Common Stock   6/11/2019     S    800   D $3.61   1015200   D   (1)  
Common Stock   6/11/2019     S    0   D $0   1015200   I   See Footnote   (1)
Common Stock   6/11/2019     S    5944   D $3.38   1009256   D   (1)  
Common Stock   6/11/2019     S    0   D $0   1009256   I   See Footnote   (1)
Common Stock   6/11/2019     S    2918   D $3.17   1006338   D   (1)  
Common Stock   6/11/2019     S    0   D $0   1006338   I   See Footnote   (1)
Common Stock   6/11/2019     S    2200   D $3.02   1004138   D   (1)  
Common Stock   6/11/2019     S    0   D $0   1004138   I   See Footnote   (1)
Common Stock   6/11/2019     S    23362   D $3.01   980776   D   (1)  
Common Stock   6/11/2019     S    0   D $0   980776   I   See Footnote   (1)
Common Stock   6/11/2019     S    11705   D $3.00   969071   D   (1)  
Common Stock   6/11/2019     S    0   D $0   969071   I   See Footnote   (1)
Common Stock   6/11/2019     S    8082   D $2.91   960989   D   (1)  
Common Stock   6/11/2019     S    0   D $0   960989   I   See Footnote   (1)
Common Stock   6/11/2019     S    64213   D $2.66   896776   D   (1)  
Common Stock   6/11/2019     S    0   D $0   896776   I   See Footnote   (1)
Common Stock   6/11/2019     S    3000   D $2.53   893776   D   (1)  
Common Stock   6/11/2019     S    0   D $0   893776   I   See Footnote   (1)
Common Stock   6/11/2019     S    50000   D $2.57   843776   D   (1)  
Common Stock   6/11/2019     S    0   D $0   843776   I   See Footnote   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation (the "Master Fund"), and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(2)  This constitutes the weighted average purchase price. The prices range from $3.69 to $4.05. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Remarks:
This is the first part of a Form 4 filing for the Reporting Persons. There are two parts to this Form 4 filing because of the constraint of a 30 transaction line maximum for tables in a Form 4.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10022

X

Armistice Capital Master Fund Ltd.
C/O DMS CORPORATE SERVICES LTD.
20 GENESIS CLOSE, P.O. BOX 314
GRAND CAYMAN, E9 KY1-1104

X

Boyd Steven
C/O ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10022

X


Signatures
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member 6/13/2019
** Signature of Reporting Person Date

Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd, Director 6/13/2019
** Signature of Reporting Person Date

/s/ Steven Boyd 6/13/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Achieve Life Sciences Charts.
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Achieve Life Sciences Charts.